StockrabitBrowse analysts
Analyst questions

Badri Vishal Bajaj

Bajaj Shares and Securities
NATCOPHARM

Natco Pharma Limited

All company calls
Natco Pharma Limited CC-Dec24.pdf
13 Feb 2025
Open call
  1. Yes, good morning. Thanks for the opportunity.

    Read in transcript
  2. Sequential earning of segment-wise revenue in export of formulation products. Basic reason I wanted to know that it has fallen below 25% if you take Q2 to Q3 of 2025. So, reason for this sudden fall, please enlighten us, sir? Thank you.

    Read in transcript
  3. No, it is very significant on our earnings also. That is what. Is it the only reason or any other?

    Read in transcript
+1 more question in this call